GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prothena Corp PLC (NAS:PRTA) » Definitions » Cyclically Adjusted FCF per Share

Prothena (Prothena) Cyclically Adjusted FCF per Share : $-1.93 (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Prothena Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Prothena's adjusted free cash flow per share for the three months ended in Dec. 2023 was $-0.980. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1.93 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-04-30), Prothena's current stock price is $21.19. Prothena's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $-1.93. Prothena's Cyclically Adjusted Price-to-FCF of today is .


Prothena Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Prothena's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prothena Cyclically Adjusted FCF per Share Chart

Prothena Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -1.70 -1.80 -1.93

Prothena Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.80 -1.89 -1.96 -1.89 -1.93

Competitive Comparison of Prothena's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Prothena's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prothena's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prothena's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Prothena's Cyclically Adjusted Price-to-FCF falls into.



Prothena Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Prothena's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.98/120.1096*120.1096
=-0.980

Current CPI (Dec. 2023) = 120.1096.

Prothena Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.779 100.573 0.930
201406 0.257 100.773 0.306
201409 -0.452 100.474 -0.540
201412 -0.459 99.576 -0.554
201503 -0.538 99.975 -0.646
201506 -0.363 100.573 -0.434
201509 -0.548 100.274 -0.656
201512 -0.532 99.676 -0.641
201603 -0.743 99.676 -0.895
201606 -0.816 101.072 -0.970
201609 -1.122 100.274 -1.344
201612 -1.183 99.676 -1.426
201703 -1.128 100.374 -1.350
201706 -0.953 100.673 -1.137
201709 -0.477 100.474 -0.570
201712 -1.037 100.075 -1.245
201803 -0.821 100.573 -0.980
201806 1.457 101.072 1.731
201809 -0.846 101.371 -1.002
201812 -0.567 100.773 -0.676
201903 -0.441 101.670 -0.521
201906 -0.305 102.168 -0.359
201909 -0.230 102.268 -0.270
201912 -0.366 102.068 -0.431
202003 -0.581 102.367 -0.682
202006 -0.470 101.769 -0.555
202009 -0.488 101.072 -0.580
202012 -0.480 101.072 -0.570
202103 -0.838 102.367 -0.983
202106 0.772 103.364 0.897
202109 2.185 104.859 2.503
202112 -0.436 106.653 -0.491
202203 -0.802 109.245 -0.882
202206 -0.757 112.734 -0.807
202209 -0.666 113.431 -0.705
202212 -0.105 115.425 -0.109
202303 -0.905 117.618 -0.924
202306 -0.860 119.611 -0.864
202309 0.156 120.708 0.155
202312 -0.980 120.110 -0.980

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Prothena  (NAS:PRTA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Prothena Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Prothena's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Prothena (Prothena) Business Description

Industry
Traded in Other Exchanges
Address
77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, IRL, D02 VK60
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Executives
Karin L Walker officer: See Remarks C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Brandon S. Smith officer: Chief Operating Officer C/O PROTHENA BIOSCIENCES INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Carol D. Karp officer: Chief Regulatory Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Michael J Malecek officer: Chief Legal Officer C/O PROTHENA BIOSCIENCES, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Hideki Garren officer: Chief Medical Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Wagner M. Zago officer: Chief Scientific Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Dennis J. Selkoe director 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Helen Susan Kim director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Tran Nguyen officer: Chief Financial Officer C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gene G. Kinney officer: CSO & Head of R&D C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Dunn William H. Jr. director C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Shane Cooke director TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Richard T Collier director
Lars Ekman director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Paula K Cobb director NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453